Default company panoramic image
Logo

Avaxia Biologics, Inc.

Avaxia is a clinical stage biotech company developing gut targeted antibody therapeutics.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Lexington, MA, USA
  • Currency USD
  • Founded November 2005
  • Employees 14
  • Website avaxiabiologics.com

Company Summary

Avaxia is developing gut-targeted antibody therapeutics. Avaxia's products are designed to be safe and effective for oral administration with minimal systemic side effects. Our lead anti-TNF product, AVX-470, is in clinical development for inflammatory bowel disease and is also being developed under a government contract for GI acute radiation syndrome. Pharma partners have expressed interest in AVX-470 and we plan to license after Phase 1b.

Team

  • Default avatar
    Neil Schauer
    VP Technical Operations
    Unconfirmed

    Dr. Schauer has over 25 years of experience in the development and manufacture of biologics. Past positions included VP Process Sciences at Inspiration, Sr Director Global Biologics at Hospira, and Director Manufacturing Sciences at Biogen Idec. He also directed Technology and Product Development at Millipore. He received his Ph.D. in Anaerobic Microbiology from Virginia Polytechnic and was a post-doc at U. Georgia.

  • Default avatar
    Barbara S. Fox
    CEO
    Unconfirmed

    Barbara S. Fox, PhD, is founder and CEO of Avaxia Biologics. Dr. Fox’s previous positions have included Affiliated Entrepreneur at Oxford Bioscience Partners; founder, President and CSO of Recovery Pharmaceuticals; VP Immunology at ImmuLogic Pharmaceutical Corp.; and Associate Professor of Rheumatology at the U. Maryland School of Medicine. Dr. Fox received her PhD in Chemistry from MIT and trained as a post-doc in cellular immunology at the NIH.

  • Default avatar
    Deborah Hartman
    VP Research
    Unconfirmed

    Dr. Hartman is a scientist and senior executive with over twenty years of experience. Past positions included VP Projects for Infectious Diseases in Innovative Medicines, VP Respiratory & Inflammation Research, and VP Lead Generation DECS, all at AstraZeneca. Dr. Hartman began her career at Hoffmann-La Roche She received her Ph.D. in Cellular and Molecular Physiology from Yale University.

  • Default avatar
    Michael Rivard
    VP Corporate Development
    Unconfirmed

    Mr. Rivard joined the company as Vice President, Corporate Development, in May 2012. Mike brings over fifteen years of experience building companies in the biotechnology industry. Most recently, he served as Vice President, Corporate Development, at VaxDesign Corporation and Vice President, Corporate Development, at Galenea Corp. Mr. Rivard earned a Juris Doctor degree at UCLA School of Law and a BA in biochemistry at Bowdoin College.

  • Default avatar
    Kevin Sarney
    VP Finance and Administration
    Unconfirmed

    Prior to joining Avaxia, Mr. Sarney was interim VP Finance and Controller at various biotechnology and medical device companies. Previously, he was Corporate Controller and Principal Accounting Officer of Nitromed, a publicly traded company. He was audit supervisor within the technology assurance group of PWC. Mr. Sarney earned an M.B.A. from Boston U and an M.A. in accounting from Suffolk. Mr. Sarney is a CPA in the state of Massachusetts.

  • Default avatar
    M. Scott Harris
    Chief Medical Officer
    Unconfirmed

    Dr. Harris served as Chief Medical Officer of Napo Pharmaceuticals, Ocera Therapeutics and Tranzyme Pharmaceuticals and is currently Professor of Medicine at Georgetown University. He graduated Harvard College and Harvard Medical School and undertook postgraduate training at Johns Hopkins Hospital and Yale University. He holds an M.S. in population health from the University of Wisconsin Medical School and is board-certified in gastroenterology.

Advisors

  • Default avatar
    Lewis Geffen, Mintz, Levin
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    AbbVie, Ariel Southeast Angel Partners, Cherrystone Angels, Golden Seeds, Beacon Angels, Beta Fund,
    Unconfirmed
    Default avatar
    Boston Harbor Angels, Granite State Angels, Keiretsu Forum, Launchpad Venture Group,
    Unconfirmed
    Default avatar
    Mass Medical Angels, Maine Angels, North Country Angels, Tech Coast Angels
    Unconfirmed